## Matej SamoÅ;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5058146/publications.pdf

Version: 2024-02-01

933447 996975 45 350 10 15 citations g-index h-index papers 45 45 45 393 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. European Journal of Clinical Pharmacology, 2022, 78, 557-564.	1.9	11
2	How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved?. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110700.	1.7	0
3	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	2.3	1
4	Recurrent Ileal Variceal Bleeding as a Diagnostic and Therapeutic Challenge. Case Reports in Gastrointestinal Medicine, 2022, 2022, 1-4.	0.3	0
5	Rotational thromboelastometry in patients with type 2 diabetes and mild COVID-19 pneumonia: A pilot prospective study. Medicine (United States), 2022, 101, e29738.	1.0	1
6	The impact of atorvastatin on dabigatran plasma levels in patients with atrial fibrillation. Blood Coagulation and Fibrinolysis, 2021, 32, 69-71.	1.0	4
7	Does atorvastatin therapy change the antiâ€Xa activity in xabansâ€treated patients with atrial fibrillation?. Pharmacology Research and Perspectives, 2021, 9, e00730.	2.4	5
8	How Can Rotational Thromboelastometry as a Point-of-Care Method Be Useful for the Management of Secondary Thromboprophylaxis in High-Risk Pregnant Patients?. Diagnostics, 2021, 11, 828.	2.6	1
9	ROTEM Testing for Direct Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2021, 47, 815-823.	2.7	9
10	Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. Journal of Cardiovascular Pharmacology, 2021, 78, e122-e127.	1.9	12
11	Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases. Diagnostics, 2021, 11, 143.	2.6	6
12	Apixaban. American Journal of Therapeutics, 2021, Publish Ahead of Print, e212-e218.	0.9	0
13	The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2020, 75, 333-335.	1.9	9
14	Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation. American Journal of Therapeutics, 2020, 27, e507-e509.	0.9	3
15	Assessing the hemostasis with thromboelastometry in direct oral anticoagulants-treated patients with atrial fibrillation. Thrombosis Research, 2020, 191, 38-41.	1.7	2
16	Anti-Xa Activity-Guided Edoxaban Therapy for Cancer-Associated Venous Thromboembolism?. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	1
17	Insulinoma presenting with postprandial hypoglycemia and a low body mass index: A case report. World Journal of Clinical Cases, 2020, 8, 4169-4176.	0.8	2
18	Severe hypoglycemia due to insulin self-injection as a cause of acute ST elevation myocardial infarction. Journal of Diabetes and Metabolic Disorders, 2019, 18, 739-742.	1.9	3

#	Article	IF	Citations
19	Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?. Pediatric Cardiology, 2019, 40, 1431-1438.	1.3	8
20	Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?. Journal of Thrombosis and Thrombolysis, 2019, 48, 619-622.	2.1	4
21	Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. Seminars in Thrombosis and Hemostasis, 2019, 45, 846-850.	2.7	14
22	Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. European Journal of Clinical Pharmacology, 2019, 75, 875-877.	1.9	6
23	Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation. Journal of Diabetes Research, 2019, 2019, 1-12.	2.3	7
24	How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?. European Journal of Clinical Pharmacology, 2019, 75, 285-286.	1.9	5
25	Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study. Journal of Thrombosis and Thrombolysis, 2019, 47, 140-145.	2.1	10
26	The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e308-e313.	0.9	30
27	Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding. Blood Coagulation and Fibrinolysis, 2018, 29, 369-373.	1.0	10
28	Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?. Diabetes Research and Clinical Practice, 2018, 135, 172-177.	2.8	9
29	Insulin Pump Therapy – Influence on Body Fat Redistribution, Skeletal Muscle Mass and Ghrelin, Leptin Changes in T1D Patients. Obesity Facts, 2018, 11, 454-464.	3.4	3
30	Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1199-1207.	1.7	28
31	Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. Drugs and Aging, 2018, 35, 539-544.	2.7	10
32	Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs. Journal of Cardiovascular Pharmacology, 2018, 72, 71-76.	1.9	9
33	Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?—A Pilot Prospective Study. American Journal of Therapeutics, 2017, 24, e162-e166.	0.9	6
34	Platelet Aggregation in Direct Oral Factor Xa Inhibitors–treated Patients With Atrial Fibrillation: A Pilot Study. Journal of Cardiovascular Pharmacology, 2017, 70, 263-266.	1.9	6
35	Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy. Medicine (United States), 2017, 96, e6045.	1.0	6
36	Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 2017, 18, 609-621.	1.2	23

## Matej Samoåi

#	Article	IF	CITATIONS
37	Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal. Current Drug Metabolism, 2017, 18, 643-650.	1.2	4
38	The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Journal of Diabetes Research, 2016, 2016, 1-6.	2.3	2
39	Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of Diabetes Research, 2016, 2016, 1-7.	2.3	8
40	Ticagrelor. Blood Coagulation and Fibrinolysis, 2016, 27, 117-120.	1.0	13
41	Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences. Journal of Cardiovascular Pharmacology, 2016, 68, 391-394.	1.9	14
42	Monitoring of dabigatran therapy using Hemoclot $\hat{A}^{\otimes}$ Thrombin Inhibitor assay in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2015, 39, 95-100.	2.1	27
43	Prasugrel loading dose in diabetic patients with acute STEMI - Always sufficiently effective? Observation in two cases and review of current knowledge. Cor Et Vasa, 2014, 56, e388-e395.	0.1	2
44	Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. American Journal of Emergency Medicine, 2014, 32, 461-465.	1.6	11
45	Sticky platelets syndrome in a young patient with massive pulmonary embolism. American Journal of Case Reports, 2013, 14, 169-172.	0.8	5